Exploring Colposcopists' Attitudes Towards Use of HPV Testing as a Primary Screening Tool for Cervical Cancer in British Columbia

Journal of Obstetrics and Gynaecology Canada

Volumn 35, Issue 7, 2013, Pages 657-663

  Regier, Dean A ^a,b   Hoek, Kim van der ^a,b   Ogilvie, Gina ^c,d   Smith, Laurie ^b   Henwood, Elena ^e   Miller, Dianne M ^d   McTaggart Cowan, Helen ^a,b   Peacock, Stuart J ^a,b,d  

^a Canadian Centre for Applied Research in Cancer Control   (Canada)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

^c BRITISH COLUMBIA CENTRE FOR DISEASE CONTROL   (Canada)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e Children's Health Centre of British Columbia   (Canada)

Author keywords

Attitudes; Cervical cancer; Human papillomavirus DNA test; Knowledge translation

Indexed keywords

ADULT; ARTICLE; ATTITUDE TO HEALTH; AWARENESS; BRITISH COLUMBIA; CANCER RISK; CANCER SCREENING; COLPOSCOPIST; CONTROLLED STUDY; EVIDENCE BASED MEDICINE; FEMALE; GENERAL PRACTITIONER; GEOGRAPHIC DISTRIBUTION; GYNECOLOGIST; HEALTH CARE PERSONNEL; HUMAN; HUMAN PAPILLOMAVIRUS DNA TEST; LOWEST INCOME GROUP; MIDDLE AGED; OBSTETRICIAN; PATIENT ADVOCACY; QUESTIONNAIRE; SEXUALLY TRANSMITTED DISEASE; SOCIAL STATUS; SOCIAL STIGMA; TREATMENT PLANNING; UTERINE CERVIX CANCER; ATTITUDES; CANADA; COLPOSCOPY; DNA PROBE; GENETICS; HEALTH CARE SURVEY; HEALTH PERSONNEL ATTITUDE; KNOWLEDGE TRANSLATION; MASS SCREENING; METHODOLOGY; PAPILLOMA VIRUS; PAPILLOMAVIRUS INFECTION; PSYCHOLOGICAL ASPECT; QUALITATIVE RESEARCH; TRANSLATIONAL RESEARCH; UTERINE CERVIX TUMOR; VIROLOGY;

DIAGNOSTIC AGENT;

ATTITUDES; CERVICAL CANCER; HUMAN PAPILLOMAVIRUS DNA TEST; KNOWLEDGE TRANSLATION;

ATTITUDE OF HEALTH PERSONNEL; BRITISH COLUMBIA; COLPOSCOPY; DNA PROBES, HPV; FEMALE; HEALTH CARE SURVEYS; HUMANS; MASS SCREENING; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; QUALITATIVE RESEARCH; QUESTIONNAIRES; TRANSLATIONAL MEDICAL RESEARCH; UTERINE CERVICAL NEOPLASMS;

EID: 84885088631     PISSN: 17012163     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1701-2163(15)30889-6     Document Type: Article

References (25)

1. Canadian Cancer Society Canadian cancer statistics 2012, Canadian Cancer Society, Toronto, ON.
2. Walboomers J.M., Jacobs M.V., Manos M.M., Bosch F.X., Kummer J.A., Shah K.V., et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999, 189(1):12-19.
3. Munoz N., Bosch F.X., de Sanjose S., Herrero R., Castellsague X., Shah K.V., et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J med 2003, 348(6):518-527.
4. Munoz N. Human papillomavirus and cancer: the epidemiological evidence. J Clin Virol 2000, 19(1-2):1-5.
5. Laara E., Day N.E., Hakama M. Trends in mortality from cervical cancer in the Nordic countries: association with organised screening programmes. Lancet 1987, 1(8544):1247-1249.
6. Christopherson W.M., Lundin F.E., Mendez W.M., Parker J.E. Cervical cancer control: a study of morbidity and mortality trends over a twenty- one-year period. Cancer 1976, 38(3):1357-1366.
7. Miller A.B., Lindsay J., Hill G.B. Mortality from cancer of the uterus in Canada and its relationship to screening for cancer of the cervix. Int J Cancer 1976, 17(5):602-612.
8. Johannesson G., Geirsson G., Day N. The effect of mass screening in Iceland, 1965-74, on the incidence and mortality of cervical carcinoma. Int J Cancer 1978, 21(4):418-425.
9. Sigurdsson K. Effect of organized screening on the risk of cervical cancer. Evaluation of screening activity in Iceland, 1964-1991. Int J Cancer 1993, 54(4):563-570.
10. Kulasingam S.L., Rajan R., St Pierre Y., Atwood C.V., Myers E.R., Franco E.L. Human papillomavirus testing with Pap triage for cervical cancer prevention in Canada: a cost-effectiveness analysis. BMC Med 2009, 7:69.
11. Saslow D., Castle P.E., Cox J.T., Davey D.D., Einstein M.H., Ferris D.G., et al. American Cancer Society Guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors. CA Cancer J Clin 2007, 57(1):7-28.
12. Nanda K., McCrory D.C., Myers E.R., Bastian L.A., Hasselblad V., Hickey J.D., et al. Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review. Ann Intern Med 2000, 132(10):810-819.
13. Fahey M.T., Irwig L., Macaskill P. Meta-analysis of Pap test accuracy. Am J Epidemiol 1995, 141(7):680-689.
14. Dillner J., Rebolj M., Birembaut P., Petry K.U., Szarewski A., Munk C., et al. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ 2008, 337:a1754.
15. Saslow D., Runowicz C.D., Solomon D., Moscicki A.B., Smith R.A., Eyre H.J., et al. American Cancer Society guideline for the early detection of cervical neoplasia and cancer. CA Cancer J Clin 2002, 52(6):342-362.
16. Bulkmans N.W., Rozendaal L., Snijders P.J., Voorhorst F.J., Boeke A.J., Zandwijken G.R., et al. POBASCAM, a population-based randomized controlled trial for implementation of high-risk HPV testing in cervical screening: design, methods and baseline data of 44,102 women. Int J Cancer 2004, 110(1):94-101.
17. Naucler P., Ryd W., Tornberg S., Strand A., Wadell G., Elfgren K., et al. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med 2007, 357(16):1589-1597.
18. Kitchener H.C., Almonte M., Thomson C., Wheeler P., Sargent A., Stoykova B., et al. HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial. Lancet Oncol 2009, 10(7):672-682.
19. Ronco G., Giorgi-Rossi P., Carozzi F., Confortini M., Dalla Palma P., Del Mistro A., et al. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol 2010, 11(3):249-257.
20. Anttila A., Kotaniemi-Talonen L., Leinonen M., Hakama M., Laurila P., Tarkkanen J., et al. Rate of cervical cancer, severe intraepithelial neoplasia, and adenocarcinoma in situ in primary HPV DNA screening with cytology triage: randomised study within organised screening programme. BMJ 2010, 340:c1804.
21. Rijkaart D.C., Berkhof J., Rozendaal L., van Kemenade F.J., Bulkmans N.W., Heideman D.A., et al. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial. Lancet Oncol 2012, 13(1):78-88.
22. Murphy J., Kennedy E.B., Dunn S., McLachlin C.M. Fung Kee Fung M, Gzik D, et al. Cervical screening: a guideline for clinical practice in Ontario. J Obstet Gynaecol Can 2012, 34(5):453-458.
23. Health Council of the Netherlands.Population screening for cervical cancer The Hauge Health Council of the Netherlands Accessed April 25, 2013. http://www.gezondheidsraad.nl/sites/%20default/files/201107E%20PopulationSCC_0.pdf.
24. Ogilvie G.S., Krajden M., van Niekerk D.J., Martin R.E., Ehlen T.G., Ceballos K., et al. Primary cervical cancer screening with HPV testing compared with liquid-based cytology: results of round 1 of a randomised controlled trial-the HPV FOCAL Study. Br J Cancer 2012, 107:1917-1924.
25. Regier D.A., Diorio C., Ethier M.C., Alli A., Alexander S., Boydell K.M., et al. Discrete choice experiment to evaluate factors that influence preferences for antibiotic prophylaxis in pediatric oncology. PloS One 2012, 7(10).